<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1052">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 01, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02465918</url>
  </required_header>
  <id_info>
    <org_study_id>H15-01420</org_study_id>
    <nct_id>NCT02465918</nct_id>
  </id_info>
  <brief_title>Cyclization of Motor Cortex Stimulation</brief_title>
  <official_title>The Relationship Between Cyclizing Stimulation and Effective Stimulation During Motor Cortex Stimulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <authority>Canada: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Motor cortex stimulation (MCS) is a form of brain stimulation for patients with neuropathic
      pain not responsive to medication. An electrode is placed on the surface of the brain and
      connected to a programmable battery in the chest.

      The strength of stimulation can be individually adjusted by changing the voltage of
      stimulation. A too high voltage will produce side effects (e.g. seizures) while a too low
      voltage will not provide pain control.

      The aim of this study is to analyze the optimal stimulation timing parameters in patients
      already implanted with MCS and have received good pain relief. The investigators wish to
      cyclize on/off MCS in order to save the battery life of the stimulator and also decrease
      stimulus habituation. The investigators hope to determine these timing parameters while
      maintaining optimal pain relief.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in Pain measured on the Visual Analogue Scale (VAS) with different stimulation settings</measure>
    <time_frame>At the End of each trial period, typically 14 days after change in stimulation settings</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life assessment with the SF-36 questionnaire</measure>
    <time_frame>At the end of each trial period, typically at 14 days after change in stimulation settings</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Pain assessment with the McGill pain questionnaire to record impact of pain</measure>
    <time_frame>At the end of each trial period, typically 14 days after change in stimulation setting</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Neuropathic Pain</condition>
  <arm_group>
    <arm_group_label>Original Setting- MCS 30 min off/0 min off</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients at baseline with their original MCS settings: on 30 minutes, off 0 minutes in any single half-hour.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MCS 25 min on/5 min off</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient MCS settings programmed to: on 25 minutes, off 5 minutes in any single half-hour.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MCS 20 min on/10 min off</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient MCS settings programmed to: on 20 minutes, off 10 minutes in any single half-hour.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MCS 15 min on/15 min off</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient MCS settings programmed to: on 15 minutes, off 15 minutes in any single hour.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>motor cortex stimulation (Change of Stimulation Timing)</intervention_name>
    <arm_group_label>Original Setting- MCS 30 min off/0 min off</arm_group_label>
    <arm_group_label>MCS 25 min on/5 min off</arm_group_label>
    <arm_group_label>MCS 20 min on/10 min off</arm_group_label>
    <arm_group_label>MCS 15 min on/15 min off</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patient more than 18 years of age

          -  Chronic neuropathic pain effectively treated with motor cortex stimulation

          -  Stable medication during the trial

          -  Willing and able to comply with the study protocol and to return per the follow-up
             visit schedule and able to provide informed consent.

        Exclusion Criteria:

          -  Evidence of an active disruptive psychiatric disorder or other known condition
             significant enough to impact the perception of pain, compliance to intervention
             and/or ability to evaluate treatment outcome as determined by the investigator

          -  Technical malfunction of the MCS device

          -  History of seizures

          -  Unable to provide informed consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher R Honey, MD, DPhil</last_name>
      <phone>604.875.5894</phone>
      <email>chris.honey@telus.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Tsubokawa T, Katayama Y, Yamamoto T, Hirayama T, Koyama S. Treatment of thalamic pain by chronic motor cortex stimulation. Pacing Clin Electrophysiol. 1991 Jan;14(1):131-4.</citation>
    <PMID>1705329</PMID>
  </results_reference>
  <results_reference>
    <citation>Tsubokawa T, Katayama Y, Yamamoto T, Hirayama T, Koyama S. Chronic motor cortex stimulation for the treatment of central pain. Acta Neurochir Suppl (Wien). 1991;52:137-9.</citation>
    <PMID>1792954</PMID>
  </results_reference>
  <results_reference>
    <citation>Peyron R, Garcia-Larrea L, Deiber MP, Cinotti L, Convers P, Sindou M, Maugui√®re F, Laurent B. Electrical stimulation of precentral cortical area in the treatment of central pain: electrophysiological and PET study. Pain. 1995 Sep;62(3):275-86.</citation>
    <PMID>8657427</PMID>
  </results_reference>
  <results_reference>
    <citation>Lima MC, Fregni F. Motor cortex stimulation for chronic pain: systematic review and meta-analysis of the literature. Neurology. 2008 Jun 10;70(24):2329-37. doi: 10.1212/01.wnl.0000314649.38527.93. Review.</citation>
    <PMID>18541887</PMID>
  </results_reference>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>November 20, 2015</lastchanged_date>
  <firstreceived_date>June 4, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Christopher Honey</investigator_full_name>
    <investigator_title>Associate Professor/Neurosurgeon</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
